To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.
Maurizio Battaglia Parodi is currently working at the Department of Ophthalmology, Scientific Institute San Raffaele in
Milan, and is Associate Professor at University Vita-Salute in Milan. He had previous appointments in the Departments of
Ophthalmology at the University of Trieste and University of Udine. Prof Battaglia Parodi’s major clinical and research interests
include age-related macular degeneration (AMD), vascular diseases and dystrophies. He has taken part in many international
clinical trials, and has authored over 210 peer-reviewed scientific articles and three books. Prof Battaglia Parodi has received
many awards for his scientific activity and is a reviewer for the most important international journals.
W elcome to the latest edition of European Ophthalmic Review, which features a wide range of articles, beginning with intraocular
diseases. An editorial from Rodrigues and Lim explores approaches to achieving successful outcomes and minimising complications
in neovascular glaucoma surgery. Also on the subject of glaucoma, Feijoo discusses the latest advances in tonometry. Biologic targeted
therapies are transforming the treatment of uveitis. Taylor discusses the latest clinical advances in this field.
Optical coherence tomography angiography (OCTA) is an emerging, non-invasive imaging technique that generates three-dimensional
images without the need for intravenous dyes. This technology has numerous potential applications for retinal vascular disease. Turgut
and Reznicek each present reviews of the advantages and disadvantages of OCTA. In addition, Iuliano describes the application of OCTA
to chorodial neovascularisations.
Diabetic macular oedema continues to present a major health challenge worldwide. Augustin presents a review of findings from clinical
trials and real-world studies. While clinical trial data have shown comparable outcomes between vascular endothelial growth factor
(VEGF) inhibitors and corticosteroids, real-world findings suggest that lower injection frequencies of VEGF are associated with less
impressive outcomes. Sustained delivery of corticosteroids has shown similar efficacy in clinical and real-world studies.
Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly. In an expert review of a symposium presented
at the 15th EURETINA Congress, Korobelnik et al discuss the use of aflibercept in AMD, including recent real-world data indicating that
aflibercept can be given with reduced dosing frequency.
Finally, Michels and Wirth present an update of the management of branch retinal vein occlusion, including established and emerging
European Ophthalmic Review would like to thank our Editorial Board for their continuing support and guidance. A special thanks also goes
to our authors, who gave their time and effort to produce an insightful selection of articles. The expert discussions and the range of topics
covered ensure there is something of interest for every reader and we hope you find this edition useful. ■
© TO U CH MED ICA L MEDIA